Skip to content

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07052539
Enrollment
60
Registered
2025-07-04
Start date
2022-07-22
Completion date
2026-07-31
Last updated
2025-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Obesity (Disorder)

Brief summary

This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.

Interventions

OTHERHigh protein and sodium meal

Meal with 1g/kg protein content and 3900mg sodium

Sponsors

University of Mississippi Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Criteria for Cohort 1: Healthy Participants Inclusion Criteria: * Adults 18-75 years old * Normal kidney function * No heart failure * BMI 25-30kg/m2

Exclusion criteria

* Diagnosis of chronic illness * eGFR\<60mL/min/1.73m2 * Pregnancy or breast feeding * History of cutaneous or allergic reaction to iodine-based products of contrast dyes * Hemoglobin levels \<7mg/dL * Acute illness or hospitalization event within 3 months * Unable to stop NSAIDs * Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism * Current use of nicotine or recreational drugs, chronic drinker Criteria for Cohort 2: Obese Participants without HFpEF Inclusion Criteria: * Adults 18-75 years old * eGFR \>= 60 mL/min/1.73m2 * BMI \> 35 kg/m2

Design outcomes

Primary

MeasureTime frame
Change in measured GFR5 hours
Change in urine sodium excretion5 hours

Countries

United States

Contacts

Primary ContactTekka Johnson
tjohnson23@umc.edu601-496-7834

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026